Global Motion Sickness Drugs Market Size By Type (Anticholinergics, Antihistamines), By Application (Hospital, Research institute), By Region, And Segment Forecasts, 2023 to 2032

The Global Motion Sickness Drugs Market was valued at USD 610 million in 2023 and is projected to surpass USD 940 million by 2031, growing at a CAGR of 5.5% during the forecast period of 2023–2031. This market is primarily driven by the increasing prevalence of motion sickness due to rising travel activity—particularly air and sea travel—and growing awareness about available pharmacological treatments. The expanding elderly population and individuals with vestibular disorders are also contributing to the increasing demand for motion sickness medications.

Drivers

1. Rising Global Travel and Tourism:

With more people traveling for business and leisure, particularly on airplanes, cruises, and road trips, the incidence of motion sickness has grown. This increase in travel activity is directly contributing to the rising consumption of motion sickness drugs.

2. Growing Geriatric Population:

Elderly individuals are more prone to experiencing motion sickness due to age-related vestibular dysfunction. The global aging trend thus supports consistent demand for motion sickness treatments.

3. Availability of Multiple Drug Forms:

The wide range of drug formulations, including tablets, patches, syrups, and chewables, enhances convenience and accessibility, promoting greater adoption across age groups.

Restraints

1. Side Effects and Contraindications:

Many motion sickness drugs are associated with side effects such as drowsiness, dry mouth, and blurred vision. These issues may deter some users, especially those needing to remain alert (e.g., drivers, machine operators).

2. Availability of Non-Pharmaceutical Alternatives:

Increased preference for natural remedies, acupressure bands, and other non-pharmacologic interventions in some demographics may limit pharmaceutical market expansion.

Opportunity

1. Product Innovation and OTC Penetration:

The development of non-drowsy formulations and fast-acting over-the-counter (OTC) medications presents a substantial opportunity. Expansion into untapped markets in Asia-Pacific and Latin America also offers high growth potential.

2. E-commerce and Telehealth Expansion:

The rise of online pharmacies and virtual health consultations has made it easier for consumers to access motion sickness drugs globally, especially in rural or underserved areas.

Market by System Type Insights

By system type, Antihistamines dominated the market in 2023, accounting for the largest share due to their widespread use and efficacy. These include popular drugs like dimenhydrinate and meclizine, which are often used as first-line treatments. Anticholinergic drugs, such as scopolamine patches, are also gaining traction for their prolonged effect, especially for sea travel.

Market by End-Use Insights

The Hospital Pharmacy segment led the market in 2023, driven by rising in-patient care for vestibular issues and increased prescription-based drug distribution. The Retail Pharmacy segment is expected to grow at the fastest rate, supported by the availability of OTC drugs and growing consumer self-medication trends.

Market by Regional Insights

North America held the largest market share in 2023 due to high awareness, widespread use of OTC medications, and well-developed healthcare infrastructure. However, Asia-Pacific is projected to witness the fastest growth rate during the forecast period, supported by a surge in travel activity, growing disposable incomes, and increasing adoption of western medication practices.

Competitive Scenario

Key players in the Global Motion Sickness Drugs Market include:

GlaxoSmithKline plc

Pfizer Inc.

Prestige Consumer Healthcare Inc.

Baxter International Inc.

Myungmoon Pharm Co., Ltd.

WellSpring Pharmaceutical Corporation

Caleb Pharmaceuticals Inc.

Bayer AG

Sanofi

Perrigo Company plc

These companies are investing in research for safer and more effective drug formulations while also focusing on expanding their product availability via OTC and e-commerce channels.

Scope of Work – Global Motion Sickness Drugs Market

Key Market Developments

April 2024: Prestige Consumer Healthcare launched a new non-drowsy version of Dramamine for sensitive users.

October 2023: Pfizer expanded its OTC product line in Southeast Asia with a new fast-dissolving tablet for motion sickness.

June 2023: Sanofi partnered with an online pharmacy platform in India to boost distribution of its motion sickness product line.

FAQs

1) What is the current market size of the Global Motion Sickness Drugs Market?

The market was valued at USD 610 million in 2023.

2) What is the major growth driver of the Global Motion Sickness Drugs Market?

Rising global travel activity and growing awareness of treatment options are the primary drivers.

3) Which is the largest region during the forecast period in the Global Motion Sickness Drugs Market?

North America held the largest share in 2023, though Asia-Pacific is expected to witness the highest growth.

4) Which segment accounted for the largest market share in Global Motion Sickness Drugs Market?

The Antihistamines segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Motion Sickness Drugs Market?

GlaxoSmithKline plc, Pfizer Inc., Sanofi, Bayer AG, and Prestige Consumer Healthcare Inc. are among the leading players.